Acro Biomedical Co., Ltd.

OTCPK:ACBM Stock Report

Market Cap: US$42.0k

Acro Biomedical Past Earnings Performance

Past criteria checks 0/6

Acro Biomedical's earnings have been declining at an average annual rate of -2.6%, while the Healthcare industry saw earnings growing at 6.2% annually. Revenues have been declining at an average rate of 59.8% per year.

Key information

-2.6%

Earnings growth rate

-1.3%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate-59.8%
Return on equity-4,459.2%
Net Margin-4,207.2%
Last Earnings Update30 Jun 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Acro Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ACBM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 230-1569
31 Mar 230-16610
31 Dec 221-16610
30 Sep 221-16610
30 Jun 221-15510
31 Mar 221-1248
31 Dec 211-835
30 Sep 211-413
30 Jun 211-101
31 Mar 210000
31 Dec 201000
30 Sep 201000
30 Jun 201000
31 Mar 201000
31 Dec 190000
30 Sep 191010
30 Jun 194010
31 Mar 196010
31 Dec 188000
30 Sep 188000
30 Jun 186000
31 Mar 184000
31 Dec 172000
30 Sep 171000
30 Jun 170000
31 Mar 170000
31 Dec 160000
30 Sep 160000
30 Jun 160000
31 Mar 160000
31 Dec 150000

Quality Earnings: ACBM is currently unprofitable.

Growing Profit Margin: ACBM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ACBM's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ACBM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACBM is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8%).


Return on Equity

High ROE: ACBM has a negative Return on Equity (-4459.2%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/12 09:24
End of Day Share Price 2024/07/15 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acro Biomedical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution